身体活动对阿尔茨海默病患者认知功能的影响:元分析
Shengyu Dai1, Shunling Yuan1, Xinbi Zhang2,3
1School of Physical Education and Sport Science, Fujian Normal University, 350117 Fuzhou, Fujian, China.
Journal of integrative neuroscience
|January 29, 2026
概括
身体活动显著改善了阿尔茨海默氏症患者的认知功能.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 运动科学 运动科学
背景情况:
- 身体活动 (PA) 是对阿尔茨海默病 (AD) 的一种公认的非药物治疗方法.
- 现有研究表明,PA可以提高AD患者的认知功能.
- 在关于确认的AD诊断和干预参数相互作用的元分析中存在差距.
研究的目的:
- 研究身体活动对阿尔茨海默病患者认知功能的影响.
- 系统地评估不同的体育活动干预参数如何影响效果大小.
主要方法:
- 系统地搜索6个数据库 (PubMed,科学网络,Embase,Cochrane,CNKI,VIP),这些数据库都遵循了PRISMA的指导方针.
- 从开始到2025年3月31日,包括随机临床试验 (RCT).
- 使用Cochrane手册标准进行方法质量评估,并通过Stata 15.0.0进行分析.
主要成果:
- 对13项涉及813名AD患者的RCT进行的元分析显示,MMSE得分与PA显著改善 (WMD = 1.79).
- 亚组分析显示,适度强度,30分钟的会议,每周>3次会议,每周>120分钟的总时间,持续时间>12周的最佳效果.
- 超回归表明干预频率和总持续时间与认知改善有积极的相关性.
结论:
- 身体活动干预措施有效地改善了阿尔茨海默病患者的迷你精神状态检查 (MMSE) 成绩.
- 建议的PA干预参数:中等强度,30分钟的会议,每周>3次,每周>120分钟的总时间,持续时间>12周.
- 普罗斯佩罗 登记:CRD420250631766. 登记时间:
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:30Cognitive Development During Adulthood
1.4K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
34
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
34